

ASX Announcement

Regeneus receives R&D tax incentive of \$2.6m

Sydney, Australia – 29 August 2017

Regeneus (ASX: RGS), a clinical-stage regenerative medicine company, today reported that it has received \$2.6m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2017.

The Research and Development (R&D) tax incentive encourages companies to engage in R&D and innovation, benefiting Australia, by providing a tax offset for eligible R&D activities.

ENDS

About Regeneus:

Regeneus Ltd is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

Contact for further information:

Sandra McIntosh
Company Secretary and Investor Relations
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au or go to <http://www.regeneus.com.au>

For personal use only